Genmab — Januar 2026

[w]

har du de fire første tal til
aftenens trækning?

[Raun]

Vi har set dette scenarie så mange gange efterhånden. Så absolut ingen overraskelse her. - aktien er styret og absolut ikke modtagelig for TA

[concillado]

Enig. En hurtig gevinsthjemtagning og mulighed for supplering, når den ryger tilpas ned i bunden af kanalen (igen-igen).

[E_L]

on the EGFR x cMet crowded space - Two more companies try to outdo Rybrevant https://www.oncologypipeline.com/apexonco/two-more-companies-try-outdo-rybrevant

[E_L]

H.C. Wainwright has reiterated a Buy rating and $39.00 price target on Genmab A/S (NASDAQ:GMAB) following FDA approval of DARZALEX FASPRO for newly-diagnosed multiple myeloma patients.
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-genmab-stock-at-39-price-target-93CH-4469885

[E_L]

an extra arm in the original Petosemtamab trial for Colorectal Cancer with FOLFOX chemo https://clinicaltrials.gov/study/NCT03526835?tab=history&a=6&b=7#version-content-panel they now also mention Esophageal Cancer separately from
Gastroesophageal-junction Cancer

[gentogen]

I think they just had forgotten to mention this as an included condition as Esophageal Cancer is also mentioned as a closed arm. Thay have added the info that "Enrollment is currently being explored in mCRC (RAS/RAF wild type) patients in the 3L/4L/5L" (i.e.metastatic colorectal cancer). All other arms seem to be closed.

[gentogen]

But: "Other expansion cohorts may be considered for monotherapy or combination treatment in the future."

[E_L]

Roche FY 2025 CHF: Ocrevus 7,010 (Q4 25 1,688), Columvi 288 , Lunsumio 114

[E_L]

EGFR x cMet - The line-up is revealed to include Merck & Co and J&J itself. https://www.oncologypipeline.com/apexonco/node/1874

[KWC]

Blev der handlet
en del aktier hen mod luk ???

[gdn55]

Ja det blev det. Hvorfor er der ingen der ved, måske

[Vitus]

Vi må i sandhed også sige det er en tavs og usynlig ledelse Genmab har anskaffet sig….

[Solsen]

Det er vel også en “stille periode” op til regnskab.

[E_L]

The collective assessment of analysts
points to an estimated 'Net Revenue- Epkinly- International' of $48.50 million. --U.S' will reach $26.75 million. https://ca.finance.yahoo.com/news/stay-ahead-game-abbvie-abbv-141510153.html